News

Ravi Agrawal, a promoter of Ajanta Pharma Limited, has released a pledge on 54,796 equity shares of the company, citing Excess Pledge as the reason. The release involved multiple transactions between August 6 and August 12, 2026, with lenders including Deutsche Investments India Pvt Ltd, Bajaj Finance Limited, INFINA FINANCE LIMITED, and Tata Capital Limited, facilitated through Barclays Securities (India) Private Limited.

Ajanta Pharma announced that the Board of Directors of the Company at its meeting held on 30 July 2026, inter alia, have recommended the First Interim dividend of Rs 32 per equity Share (i.e. 1600%) , subject to the approval of the shareholders.

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2026.

Ajanta Pharma announced that the 47th Annual General Meeting(AGM) of the company will be held on 16 July 2026.

Net profit of Ajanta Pharma rose 18.40% to Rs 266.70 crore in the quarter ended March 2026 as against Rs 225.26 crore during the previous quarter ended March 2025. Sales rose 21.47% to Rs 1421.64 crore in the quarter ended March 2026 as against Rs 1170.41 crore during the previous quarter ended March 2025.For the full year,net profit rose 14.73% to Rs 1056.00 crore in the year ended March 2026 as against Rs 920.39 crore during the previous year ended March 2025. Sales rose 17.31% to Rs 5452.86 crore in the year ended March 2026 as against Rs 4648.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1421.641170.41 21 5452.864648.10 17 OPM %23.4525.39 -25.5827.10 - PBDT392.48309.19 27 1550.791333.27 16 PBT347.11269.41 29 1377.651189.16 16 NP266.70225.26 18 1056.00920.39 15 Powered by Capital Market - Live News